Boosters reduce vulnerability to COVID-19 variants
Omicron, a new COVID-19 variant of concern, has been detected in all regions of the world, including North America. While research and clinical observations on the new strain are underway, it is not yet known what impact, if any, omicron will have on the immune response, transmissibility, or specific COVID-19 treatments.
The emergence of omicron is a reminder to take important steps to protect yourself against COVID-19.
Dr. Poland is encouraged by vaccine booster rates in the U.S. "In a relatively short period of time, about 36% of adults who are eligible have indeed gotten a booster," says Dr. Poland. "There's plenty of vaccine available. So in the strongest possible terms, I would recommend getting that booster."
Adults who are six months past completing their initial Moderna or Pfizer COVID-19 vaccination series are eligible to receive a booster dose, as are adults who are two months past completing their initial dose of the Johnson & Johnson vaccine.
On the Mayo Clinic Q&A podcast, Dr. Poland discusses the omicron variant and COVID-19 boosters, and he answers some listener questions.
To practice safe social distancing during the COVID-19 pandemic, this interview was conducted using video conferencing. The sound and video quality are representative of the technology used. For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, where social distancing and other safety protocols were followed.
Connect with others talking about the pandemic and supporting one another in the COVID-19 support group.
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.